Exclusive Summary

• The product has US FDA GMP certification and has been registered in the US, indicating excellent quality and compliance, making it easy to access mainstream global markets.
• Irbesartan and Hydrochlorothiazide Tablets, as a standard first-line/second-line combination therapy for hypertension, has a continuous and huge market demand globally due to the large patient base.
• The original patent has expired, and the market competition landscape is stable, providing stable growth space and commercial opportunities for generics, especially suitable for rapid market expansion through distribution.
• It offers a significant cost advantage compared to the originator drug, leading to healthcare cost savings and strong competitiveness in cost-effective focused markets.
• Chinese suppliers possess stable supply capabilities and cost control advantages, providing reliable and economical product sources for global partners.